Juana María Cano Cano-rekin lankidetzan egindako argitalpenak (9)

2024

  1. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry

    Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145

  2. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

    Clinical and Translational Oncology

2023

  1. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089

  2. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

    Therapeutic Advances in Medical Oncology, Vol. 15

2022

  1. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    ESMO Open, Vol. 7, Núm. 3

2021

  1. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  2. External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

    Gastric Cancer, Vol. 24, Núm. 2, pp. 445-456

  3. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

    Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936

2020

  1. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry

    PloS one, Vol. 15, Núm. 7, pp. e0235848